In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares ...

Canada is just emerging from another winter wave of multiple infectious diseases only for the population to be confronted ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

Pharmaceutical bosses and the government are racing to stop Donald Trump from slapping tariffs on medicines in a move that ...

London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards ...

Learn more about whether Amicus Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

The Global Active Pharmaceutical Ingredients Market achieved a valuation of $209.80 Billion in 2024 and is anticipated to ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2916. The stock has experienced fluctuations ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The United States should avoid imposing tariffs on pharmaceutical imports, as such measures would disrupt global medical supply chains, drive up healthcare costs for American consumers, and undermine ...

The Centers for Disease Control and Prevention (CDC) has recently updated its vaccine recommendations for three critical diseases: meningococcal, respiratory syncytial virus (RSV), and chikungunya.